Showing 741 - 760 results of 230,677 for search '(( 5 ((non decrease) OR (point decrease)) ) OR ( 10 ((we decrease) OR (a decrease)) ))', query time: 1.69s Refine Results
  1. 741
  2. 742
  3. 743
  4. 744

    Nur77 knockdown decreases cell viability and proliferation. by Alexa Tenga (2161780)

    Published 2016
    “…<p>(A) Daoy cells were transfected with 20 nM siNur77 or non-targeting control (NT), and cell viability was measured via the CellTiter-Glo assay every day for 3 days. …”
  5. 745

    S5 Fig - by Meghan J. Hirsch (16528311)

    Published 2023
    “…Our model shows with an inoculum of 2 x 10<sup>2</sup> CFUs of PA for 24 hours pro-inflammatory markers such as interleukin 6 and interleukin 8 are upregulated with little decrease in CF bronchial epithelial cell survival or monolayer confluency. …”
  6. 746

    Decreased HIF levels associated with hyperoxic cell state. by Julie M. Koeman (108185)

    Published 2008
    “…<p>(A) Normalized densitometry of HIF-1α protein levels (•),HIF-1β protein levels (▴), and HIF-1 DNA-binding activity (⧫) as presented in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000176#pgen-1000176-g005" target="_blank">Figure 5B</a> of the Jiang et al. article. …”
  7. 747

    Human preterm infants diagnosed with IUGR have decreased Paneth cell counts compared to preterm non-IUGR control infants. by Camille M. Fung (844334)

    Published 2016
    “…Infants with a diagnosis of IUGR (n = 9) were compared to age-matched non-IUGR infants (n = 4). (A) IUGR infants had similar numbers of goblet cells per 100 epithelial cells compared to non-IUGR infants (p = 0.5). …”
  8. 748

    Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>. by Giorgia Urbinati (554921)

    Published 2015
    “…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
  9. 749
  10. 750
  11. 751

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  12. 752
  13. 753
  14. 754
  15. 755
  16. 756
  17. 757
  18. 758

    Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…<p>VCaP cells were transfected for 72h from 2.5 nM to 50 nM with siRNA TMPRSS2-ERG III, siRNA TMPRSS2-ERG IV or siRNA Control. …”
  19. 759
  20. 760